A Family with Erythrocytosis Establishes a Role for Prolyl Hydroxylase Domain Protein 2 in Oxygen Homeostasis
The number of red blood cells is normally tightly regulated by a classic homeostatic mechanism based on oxygen sensing in the kidney. Decreased oxygen delivery resulting from anemia induces the production of erythropoietin, which increases red cell production and hence oxygen delivery. Investigation...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 103; no. 3; pp. 654 - 659 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
17.01.2006
National Acad Sciences |
Series | From the Cover |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The number of red blood cells is normally tightly regulated by a classic homeostatic mechanism based on oxygen sensing in the kidney. Decreased oxygen delivery resulting from anemia induces the production of erythropoietin, which increases red cell production and hence oxygen delivery. Investigations of erythropoietin regulation identified the transcription factor hypoxia-inducible factor (HIF). HIF is now recognized as being a key regulator of genes that function in a comprehensive range of processes besides erythropoiesis, including energy metabolism and angiogenesis. HIF itself is regulated through the α-subunit, which is hydroxylated in the presence of oxygen by a family of three prolyl hydroxylase domain proteins (PHDs)/HIF prolyl hydroxylases/egg-laying-defective nine enzymes. Hydroxylation allows capture by the von Hippel-Lindau tumor suppressor gene product, ubiquitination, and destruction by the proteasome. Here we describe an inherited mutation in a mammalian PHD enzyme. We show that this mutation in PHD2 results in a marked decrease in enzyme activity and is associated with familial erythrocytosis, identifying a previously unrecognized cause of this condition. Our findings indicate that PHD2 is critical for normal regulation of HIF in humans. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Case Study-2 ObjectType-Feature-4 ObjectType-Report-1 ObjectType-Article-3 Abbreviations: Epo, erythropoietin; GSH, glutathione; Hct, hematocrit; mU, milliunits; HIF, hypoxia-inducible factor; PHD, prolyl hydroxylase domain protein; VHL, von Hippel–Lindau tumor suppressor protein; HRE, hypoxia response element. M.F.M. and F.S.L. contributed equally to this work. To whom correspondence should be addressed at: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 605 Stellar Chance Labs, 422 Curie Boulevard, Philadelphia, PA 19104. E-mail: franklee@mail.med.upenn.edu. This paper was submitted directly (Track II) to the PNAS office. Edited by Steven L. McKnight, University of Texas Southwestern Medical Center, Dallas, TX, and approved November 28, 2005 Conflict of interest statement: P.H.M. is a director and consultant of and holds equity in ReOx Ltd., which aims to develop therapeutic inhibitors of the HIF hydroxylase enzymes. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.0508423103 |